Europe
Health
Female CEOs

Mylan

$28.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (0.31%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Mylan and other stocks, options, ETFs, and crypto commission-free!

About

Mylan N.V. Ordinary Shares, also called Mylan, is a pharmaceutical healthcare company. Read More The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Employees
35,000
Headquarters
Hatfield, Hertfordshire
Founded
1961
Market Cap
14.76B
Price-Earnings Ratio
42.22
Dividend Yield
0.00
Average Volume
4.84M
High Today
$29.09
Low Today
$28.54
Open Price
$28.72
Volume
2.84M
52 Week High
$42.50
52 Week Low
$26.00

Collections

Europe
Health
Female CEOs
Pharmaceutical
UK
Technology
Manufacturing

News

MarketWatch15h

Mylan N.V. Stock Quote (U.S.: Nasdaq)

Breaking Mylan NV reported smaller profit than expected in the fourth quarter and predicted earnings for 2019 would be substantially lower than analysts' projections Tuesday, pushing shares down more than 6% in late trading. The pharmaceutical giant reported fourth-quarter earnings of $51.2 million, or 10 cents a share, on sales of $3.08 billion, down from $3.24 billion a year ago. After taking out restructuring charges and other costs, the company claimed adjusted earnings of $1.30 a share, down from $1.4...

27
TradingNewsNowMar 19

Current Trend: Mylan N.V. (NASDAQ: MYL)

Mylan N.V. is part of the healthcare sector and trades as part of the drug manufacturers industry. The company CEO is Heather Bresch. Mylan NV is a generic pharmaceutical manufacturer which develops, licenses, manufactures, markets and distributes generic, over-the-counter OTC products in a variety of dosage forms and therapeutic categories. Previous Intraday Trading Performance: The MYL stock showed a previous change of 0.32% with an open at 28.09 and a close of 28.18. It reached an intraday high of 28.5...

62
Markets InsiderMar 18

Mylan Initiates Voluntary Nationwide Recall Of Levoleucovorin Injection

(RTTNews) - Mylan Institutional LLC said it is conducting a voluntary nationwide recall of two lots of Levoleucovorin Injection, 250 mg/25 mL tothe consumer/user level.

25

Earnings

$0.96
$1.12
$1.27
$1.43
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
β€”
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.